Arcturus Therapeutics shares are trading lower. The company announced that it presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with CF for ARCT-032 at the 47th European Cystic Fibrosis Conference.
Portfolio Pulse from Benzinga Newsdesk
Arcturus Therapeutics shares are trading lower following the presentation of Phase 1 results in healthy volunteers and Phase 1b interim data in people with cystic fibrosis for ARCT-032 at the 47th European Cystic Fibrosis Conference.
June 07, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arcturus Therapeutics shares are trading lower after the company presented Phase 1 and Phase 1b data for ARCT-032 at a major conference. The market reaction suggests that the data may not have met investor expectations.
The decline in share price indicates that investors were not impressed with the Phase 1 and Phase 1b data for ARCT-032. This suggests that the results may not have met market expectations, leading to a negative short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100